# ARS Pharmaceuticals, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/ARS Pharmaceuticals, Inc.).

## Overview

ARS Pharmaceuticals is a U.S.-based biopharmaceutical company built around neffy, a needle-free intranasal epinephrine product for the emergency treatment of Type I allergic reactions, including anaphylaxis. The company describes neffy as the first and only FDA- and European Commission-approved needle-free epinephrine product, with additional approvals in the U.K., Japan, Australia, and China. Its business is centered on commercializing neffy in the United States while expanding through licensing and collaboration partners in international markets. ARS also has a development program in chronic urticaria, but near-term value creation is primarily tied to neffy adoption, reimbursement, and geographic expansion.

## Products & services

• neffy 2 mg intranasal epinephrine for adults and children ≥30 kg
• neffy 1 mg intranasal epinephrine for children 15-30 kg
• EURneffy ex-U.S. branded epinephrine product
• Licensing rights for neffy in Japan, China, Australia/NZ and other territories
• Supply, development and regulatory collaboration services

- **Commercial epinephrine products** (86%) — Approved needle-free intranasal epinephrine products sold for emergency treatment of anaphylaxis.
- **Collaboration and milestone revenue** (11%) — Milestone, royalty, and service revenue from licensing and commercialization partners.
- **Supply agreements** (3%) — Revenue from supplying product or related materials to partners under collaboration arrangements.

- neffy 2 mg intranasal epinephrine for adults and children ≥30 kg
- neffy 1 mg intranasal epinephrine for children 15-30 kg
- EURneffy ex-U.S. branded epinephrine product
- Licensing rights for neffy in Japan, China, Australia/NZ and other territories
- Supply, development and regulatory collaboration services

## Customers

ARS sells primarily into the U.S. prescription allergy market, where the key buyers are healthcare providers who prescribe epinephrine for patients at risk of anaphylaxis. The company specifically targets high-volume prescribers such as allergists and pediatricians, because these physicians account for a large share of epinephrine prescriptions and are most likely to adopt a non-injectable option. In the U.S., product distribution runs through pharmaceutical wholesale distributors, which are the channel that ultimately supplies pharmacies and healthcare providers. Outside the U.S., ARS relies on licensing partners such as Alfresa, Pediatrix, Seqirus, and ALK to commercialize in their respective territories, so partner execution is critical to international uptake. Patient demand also matters because the company uses direct-to-consumer marketing to drive awareness and prescription requests for a needle-free alternative.

- **U.S. high-volume prescribers** (primary) — Allergists, pediatricians, and other prescribers who write most epinephrine prescriptions and are targeted because they can drive rapid adoption of neffy.
- **Pharmaceutical wholesale distributors** (primary) — Wholesale channels that purchase and distribute neffy in the U.S. to pharmacies and healthcare providers.
- **Patients at risk of anaphylaxis** (primary) — End users who influence prescribing through preference for a needle-free, easier-to-carry emergency treatment.
- **International commercialization partners** (secondary) — Partners such as Alfresa, Pediatrix, Seqirus, and ALK that buy rights, support development, and commercialize in non-U.S. markets.
- **Healthcare professionals in clinical challenge settings** (secondary) — Clinicians participating in the neffy experience program who use the product firsthand and may convert to prescribing it.

- Allergists who prescribe epinephrine for anaphylaxis risk
- Pediatricians treating children with severe food or environmental allergies
- Other high-volume prescribers of epinephrine in the U.S.
- Pharmaceutical wholesale distributors that distribute neffy to providers
- International licensing partners that commercialize in their territories
- Patients and caregivers seeking a non-injectable rescue option

## Geography

ARS is commercially anchored in the United States, where it launched neffy in September 2024 and generated the majority of revenue from product sales. The company also has approved products or rights in the European Union, the U.K., Japan, Australia, and China, but those markets are largely served through partners rather than a direct local sales force. Its collaboration structure splits territories among Alfresa, Pediatrix, Seqirus, and ALK, which reduces direct operating burden but increases dependence on partner execution. Geography matters because pricing, reimbursement, and regulatory pathways differ materially across the U.S., Europe, and Asia, affecting launch timing and adoption. The company’s manufacturing and supply chain are not fully detailed in the excerpts, but its business model depends on third-party manufacturers, logistics providers, and regulatory approval of raw material sources across markets.

- U.S. is the core commercial market and the main source of product revenue
- Europe is served through EURneffy and the ALK collaboration
- Japan is commercialized through Alfresa
- China is commercialized through Pediatrix under the trade name 优敏速
- Australia and New Zealand are commercialized through Seqirus
- Pricing and reimbursement are country-specific and can slow adoption
- Third-party manufacturing and logistics create cross-border supply exposure

## Strategy

ARS’s strategy is to make neffy the standard non-injectable epinephrine option by building physician awareness, patient demand, and payer access around a differentiated delivery method. In the U.S., it is concentrating on a focused sales force aimed at the highest-prescribing allergists and pediatricians, while also using direct-to-consumer marketing to create pull-through demand. Internationally, the company is using licensing and collaboration agreements to extend reach without building a large direct commercial footprint in every market. It is also pursuing pipeline expansion into chronic spontaneous urticaria, which could broaden the platform beyond emergency anaphylaxis treatment if clinical data support it.

- **Drive U.S. neffy prescription growth** (short-term) — The company’s near-term value depends on converting physician awareness into repeat prescribing and pharmacy fulfillment.
- **Increase patient pull-through and brand awareness** (short-term) — Direct consumer demand can support physician adoption and reduce reliance on field sales alone.
- **Monetize international rights through partners** (medium-term) — Partner-led commercialization can broaden geographic reach while limiting direct operating expense.
- **Advance the chronic urticaria pipeline** (medium-term) — A successful second indication could diversify the company beyond anaphylaxis and extend the neffy platform.

- Expand neffy adoption among high-volume U.S. prescribers
- Use direct-to-consumer marketing to increase patient awareness
- Scale the sales force to broaden field coverage in 2026
- Leverage partners for ex-U.S. commercialization and milestones
- Build clinical evidence in chronic urticaria to extend the platform
- Maintain supply and regulatory readiness across multiple territories

## Risks

ARS is highly dependent on the commercial success of neffy, so slower-than-expected physician adoption, payer resistance, or competitive injectable alternatives could materially limit revenue growth. Because the company relies on third-party manufacturers, logistics providers, CROs, and licensing partners, supply interruptions or partner underperformance could delay sales, require regulatory re-approval of raw materials, or reduce milestone and royalty income. As a commercial-stage biopharma company with a limited product base, it also faces the usual pharmaceutical risks around safety, labeling, reimbursement, and regulatory scrutiny in each market. Cybersecurity and data protection risks are relevant because the company uses cloud systems and third-party service providers to process sensitive clinical, commercial, and operational information. Ongoing losses and dependence on future product uptake mean that execution risk remains high until neffy generates durable, scaled demand.

- **Commercial dependence on neffy** [critical] — The company’s business model is concentrated in one approved product, so weak uptake would directly pressure revenue and valuation.
- **Supply chain and third-party manufacturing disruption** [high] — The company relies on external manufacturers and suppliers; interruptions can delay production and require regulatory re-qualification of sources.
- **Partner underperformance** [high] — International revenue and milestone opportunities depend on collaborators such as ALK, Alfresa, Pediatrix, and Seqirus.
- **Pricing and reimbursement pressure** [medium] — Prescription drug pricing can be controlled or negotiated by governments and payers, slowing uptake and reducing realized value.
- **Cybersecurity and data protection** [medium] — The company depends on cloud infrastructure, third-party providers, and remote work, increasing exposure to breaches and operational disruption.

- Dependence on neffy adoption as the main revenue driver
- Payer and pricing pressure in prescription drug markets
- Supply chain interruptions and raw material qualification delays
- Partner execution risk in Japan, China, Australia/NZ, and Europe
- Regulatory and labeling risk across multiple jurisdictions
- Cybersecurity exposure through third-party systems and remote work
- Commercial concentration risk from a single-product platform

## Accounting

ARS’s most important accounting judgments relate to revenue recognition, because revenue comes from a mix of product sales, collaboration milestones, royalties, development services, and supply agreements. Product revenue is affected by estimates for rebates, chargebacks, returns, and inventory reserves, which can move reported net sales materially as launch volumes scale. Collaboration revenue is timing-sensitive because milestone recognition depends on achievement of regulatory or commercial events, so quarterly results can be lumpy and difficult to compare. The company also has significant stock-based compensation, accrued expenses, and valuation allowance judgments typical of a development-stage biopharma company, all of which can materially affect reported losses. Because neffy commercialization only began in 2024, seasonality and launch timing can create large quarter-to-quarter swings in revenue, cost of goods sold, and operating expenses.

- **Revenue recognition for product sales and collaboration agreements** — Can shift revenue between quarters and affect gross margin presentation
- **Sales deductions and reserves** — Can materially change reported net sales as the launch scales
- **Inventory reserve and cost of goods sold** — Can distort gross margin during the launch phase
- **Stock-based compensation** — Affects operating loss and comparability across periods
- **Valuation allowance for deferred tax assets** — Can affect tax expense and equity presentation

- Net product revenue depends on rebates, chargebacks, returns, and reserves
- Milestone revenue is event-driven and can create lumpy quarterly results
- Supply and development agreements require judgment on performance obligations
- Inventory reserves matter because launch sales used some zero-cost inventory
- Stock-based compensation is a meaningful operating expense
- Valuation allowance and accrued expense estimates affect reported losses
- Launch timing creates strong quarter-to-quarter comparability issues

---

*Last updated: 2026-08-11T04:46:18.770935+00:00*